Neuraxis, Inc. Form 8-K Summary
Business Context and Reporting Period
Neuraxis, Inc. (NRXS), a Delaware corporation listed on NYSE American, filed this Current Report on July 9, 2026. The filing addresses a corporate action regarding the Company's Series B Preferred Stock for the second quarter of 2026.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the declaration of a stock dividend.
Material Changes and Corporate Actions
- Dividend Declaration: The Board of Directors authorized a stock dividend on Series B Preferred Stock for the second quarter of 2026.
- Payment Method: The dividend is paid in shares of Common Stock ($0.001 par value).
- Calculation Basis: Shares are determined by dividing accrued and unpaid dividends (from April 1, 2026, through the record date) by $2.38.
- Issuance Volume: Approximately 80,463 shares of Common Stock are expected to be issued.
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive cash equal to the fraction multiplied by $2.38.
- Key Dates:
- Record Date: July 21, 2026
- Payment Date: July 29, 2026
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items beyond the specific mechanics of the dividend distribution.
Investor Verification Checklist
- Verify the exact number of Series B Preferred shares held to calculate the specific Common Stock entitlement.
- Confirm the record date of July 21, 2026, to ensure eligibility for the dividend.
- Review the impact of the issuance of approximately 80,463 new Common Stock shares on existing shareholder dilution.
- Check the cash settlement amount for any fractional share entitlements based on the $2.38 divisor.